Skip to Content

Drugs for Hypertension


George L. Bakris

, MD, University of Chicago School of Medicine

Last full review/revision Mar 2021| Content last modified Mar 2021

A number of drug classes are effective for initial and subsequent management of hypertension:

  • Adrenergic  modifiers
  • Angiotensin-converting enzyme (ACE) inhibitors
  • Angiotensin II receptor blockers (ARBs)
  • Beta-blockers
  • Calcium channel blockers
  • Direct renin inhibitors
  • Direct vasodilators
  • Diuretics

Drug selection and use in the treatment of stable hypertension is discussed elsewhere. For drug treatment of hypertensive emergencies, see table Parenteral Drugs for Hypertensive Emergencies.

(See also Overview of Hypertension and Hypertensive Emergencies.)

Adrenergic  modifiers

Adrenergic modifiers include central alpha-2-agonists, postsynaptic alpha-1-blockers, and peripheral-acting non-selective adrenergic blockers (see table Adrenergic Modifiers for Hypertension).

Adrenergic Modifiers for Hypertension


Usual Dose

Selected Adverse Effects


Alpha-2-agonists (central acting)


0.05–0.3 mg twice a day

Drowsiness, sedation, dry mouth, fatigue, sexual dysfunction, rebound hypertension with abrupt discontinuance (particularly if doses are high or concomitant beta-blockers are continued), localized skin reaction to clonidine patch; possibly liver damage, Coombs-positive hemolytic anemia with methyldopa

Should be used cautiously in older patients because of orthostatic hypotension

Interferes with measurements of urinary catecholamine levels by fluorometric methods

Clonidine TTS (patch)

0.1–0.3 mg once a week


2–16 mg twice a day


0.5–3 mg once a day


250–1000 mg twice a day



1–16 mg once a day

First-dose syncope, orthostatic hypotension, weakness, palpitations, headache

Should be used cautiously in older patients because of orthostatic hypotension

Relieves symptoms of benign prostatic hyperplasia


1–10 mg twice a day


1–20 mg once a day

* Peripheral-acting adrenergic blockers (eg, guanadrel, guanethidine, reserpine) are no longer available in the US.

TTS = transdermal therapeutic system.

Alpha-2-agonists (eg, methyldopa, clonidine, guanabenz, guanfacine) stimulate alpha-2-adrenergic receptors in the brain stem and reduce sympathetic nervous activity, lowering blood pressure (BP). Because they have a central action, they are more likely than other antihypertensives to cause drowsiness, lethargy, and depression; they are no longer widely used. Clonidine can be applied transdermally once a week as a patch; thus, it may be useful for nonadherent patients (eg, those with dementia).

Postsynaptic alpha-1-blockers (eg, prazosin, terazosin, doxazosin) are no longer used for primary treatment of hypertension because evidence suggests no reduction in mortality. Also, doxazosin used alone or with antihypertensives other than diuretics increases risk of heart failure. However, they may be used in patients who have prostatic hypertrophy and need a 4th antihypertensive or in people with high sympathetic tone (ie, with high heart rate and spiking blood pressures) already on the maximum dose of a beta-blocker.

Angiotensin-converting enzyme (ACE) inhibitors

ACE inhibitors (see table Oral ACE Inhibitors and Angiotensin II Receptor Blockers for Hypertension) reduce blood pressure by interfering with the conversion of angiotensin I to angiotensin II and by inhibiting the degradation of bradykinin, thereby decreasing peripheral vascular resistance without causing reflex tachycardia. These drugs reduce BP in many hypertensive patients, regardless of plasma renin activity. Because these drugs provide renal protection, they are the drugs of choice for patients with diabetes. They are not recommended for initial treatment in blacks, in whom they appear to increase the risk of stroke when used for initial treatment.

A dry, irritating cough is the most common adverse effect, but angioedema is the most serious and, if it affects the oropharynx, can be fatal. Angioedema is most common among blacks and smokers. ACE inhibitors may increase serum potassium and creatinine levels, especially in patients with chronic kidney disease and those taking potassium-sparing diuretics, potassium supplements, or nonsteroidal anti-inflammatory drugs (NSAIDs). ACE inhibitors are the least likely of the antihypertensives to cause erectile dysfunction. ACE inhibitors are contraindicated during pregnancy. In patients with a renal disorder, serum creatinine and potassium levels are monitored at least every 3 months. Patients who have stage 3 nephropathy (estimated glomerular filtration rate [GFR] of  < 60 mL/minute to > 30 mL/minute) and are given ACE inhibitors can usually tolerate up to a 30 to 35% increase in serum creatinine above baseline. ACE inhibitors can cause acute kidney injury in patients who have hypovolemia, severe heart failure, severe bilateral renal artery stenosis, or severe stenosis in the artery to a solitary kidney.

Thiazide-type diuretics enhance the antihypertensive activity of ACE inhibitors more than that of other classes of antihypertensives. Spironolactone and eplerenone also appear to enhance the effect of ACE inhibitors.

Oral Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers for Hypertension


Usual Dose

Selected Adverse Effects

ACE inhibitors*


5–40 mg once a day

Rash, cough, angioedema, hyperkalemia (particularly in patients with renal insufficiency or taking nonsteroidal anti-inflammatory drugs, potassium-sparing diuretics, or potassium supplements), dysgeusia, reversible acute kidney injury if stenosis affecting one or both kidneys threatens renal function, proteinuria (rare at recommended doses), neutropenia (rare), hypotension with initiation of treatment (particularly in patients with high plasma renin activity or with hypovolemia due to diuretics or other conditions)


12.5–150 mg twice a day


2.5–40 mg once a day


10–80 mg once a day


5–40 mg once a day

Perindopril erbumine

4–8 mg once a day


5–80 mg once a day


1.25–20 mg once a day


1–4 mg once a day

Angiotensin II receptor blockers


80 mg once a day

In patients > 65, initial dose 40 mg once a day

Dizziness, angioedema (very rare); theoretically, same adverse effects as ACE inhibitors on renal function (except proteinuria and neutropenia), serum potassium, and blood pressure


8–32 mg once a day


400–1200 mg once a day


75–300 mg once a day


25–100 mg once a day


20–40 mg once a day


20–80 mg once a day


80–320 mg once a day

* All ACE inhibitors and angiotensin II receptor blockers are contraindicated in pregnancy (category C during 1st trimester; category D during 2nd and 3rd trimesters).

Angiotensin II receptor blockers (ARBs)

Angiotensin II receptor blockers (see table Oral ACE Inhibitors and Angiotensin II Receptor Blockers for Hypertension) block angiotensin II receptors and therefore interfere with the renin-angiotensin system. Angiotensin II receptor blockers and ACE inhibitors are equally effective as antihypertensives. Angiotensin II receptor blockers may provide added benefits via tissue ACE blockade. The 2 classes have the same beneficial effects in patients with left ventricular failure or with nephropathy due to type 1 diabetes. An angiotensin II receptor blocker should not be used together with an ACE inhibitor, but when used with a beta-blocker may reduce the hospitalization rate for patients with heart failure. Angiotensin II receptor blockers may be safely started in people <  60 with initial serum creatinine of ≤ 3 mg/dL (≤ 265 micromol/L).

Incidence of adverse events is low; angioedema occurs but much less frequently than with ACE inhibitors. Precautions for use of angiotensin II receptor blockers in patients with renovascular hypertension, hypovolemia, and severe heart failure are the same as those for ACE inhibitors (see table Oral ACE Inhibitors and Angiotensin II Receptor Blockers for Hypertension). Angiotensin II receptor blockers are contraindicated during pregnancy.


Beta-blockers (see table Oral Beta-Blockers for Hypertension) slow heart rate and reduce myocardial contractility, thus reducing blood pressure. All beta-blockers are similar in antihypertensive efficacy. In patients with diabetes, chronic peripheral arterial disease, or chronic obstructive pulmonary disease (COPD), a cardioselective beta-blocker (acebutolol, atenolol, betaxolol, bisoprolol, metoprolol) may be preferable, although cardioselectivity is only relative and decreases as dose increases. Even cardioselective beta-blockers are contraindicated in patients with asthma or in patients with COPD with a prominent bronchospastic component.

Oral Beta-Blockers for Hypertension


Usual Dose

Selected Adverse Effects


Acebutolol*, †

200–800 mg once a day

Bronchospasm, fatigue, insomnia, sexual dysfunction, exacerbation of heart failure, masking of symptoms of hypoglycemia, triglyceridemia, increased total cholesterol and decreased high-density lipoprotein cholesterol (except for pindolol, acebutolol, penbutolol, carteolol, and labetalol)

Contraindicated in patients with asthma, greater than 1st-degree atrioventricular block, or sick sinus syndrome

Should be used cautiously in patients with heart failure or insulin-treated diabetes

Should not be stopped abruptly in patients with coronary artery disease

Bisoprolol, carvedilol and metoprolol approved for treating heart failure


25–100 mg once a day


5–20 mg once a day


2.5–20 mg once a day


6.25–25 mg twice a day

Carvedilol (controlled-release)‡

20–80 mg once a day

Labetalol‡, §

100–900 mg twice a day


25–150 mg twice a day

Metoprolol (extended-release)

50– 400 mg once a day


40–320 mg once a day


5–40 mg once a day


10–20 mg once a day


5–30 mg twice a day


20–160 mg twice a day

Propranolol, long-acting

60–320 mg once a day


10–30 mg twice a day

* Cardioselective.

† With intrinsic sympathomimetic activity.

‡ Alpha-beta-blockers. Labetalol can also be given IV for hypertensive emergencies. For IV administration, it is started as 20 mg up to a maximum 300 mg.

§ Can also be given for hypertensive emergencies; for IV administration, started as 20 mg up to a maximum 300 mg.

Beta-blockers are particularly useful in patients who have angina, who have had a myocardial infarction, or who have heart failure, although atenolol may worsen prognosis in patients with coronary artery disease (CAD). These drugs are no longer considered problematic for the elderly.

Beta-blockers with intrinsic sympathomimetic activity (eg, acebutolol, pindolol) do not adversely affect serum lipids; they are less likely to cause severe bradycardia.

Beta-blockers have central nervous system (CNS) adverse effects (sleep disturbances, fatigue, lethargy) and exacerbate depression. Nadolol affects the CNS the least and may be best when CNS effects must be avoided. Beta-blockers are contraindicated in patients with 2nd- or 3rd-degree atrioventricular block, asthma, or sinus node dysfunction.

Calcium channel blockers

Dihydropyridines (see table Oral Calcium Channel Blockers for Hypertension) are potent peripheral vasodilators and reduce blood pressure by decreasing total peripheral vascular resistance (TPR); they sometimes cause reflexive tachycardia.

The nondihydropyridines verapamil and diltiazem slow the heart rate, decrease atrioventricular conduction, and decrease myocardial contractility. These drugs should not be prescribed for patients with 2nd- or 3rd-degree atrioventricular block or with left ventricular failure.

Oral Calcium Channel Blockers for Hypertension


Usual Dose

Selected Adverse Effects


Benzothiazepine derivatives

Diltiazem, sustained-release

60–180 mg twice a day

Headache, dizziness, asthenia, flushing, edema, negative inotropic effect; possibly liver dysfunction

Contraindicated in heart failure due to systolic dysfunction, in sinus node dysfunction, or in greater than 1st-degree atrioventricular block

Diltiazem, extended-release

120–360 mg once a day

Diphenylalkylamine derivatives


40–120 mg 3 times a day

Same as for benzothiazepine derivatives, plus constipation

Same as for benzothiazepine derivatives

Verapamil, sustained-release

120–480 mg once a day



2.5–10 mg once a day

Dizziness, flushing, headache, weakness, nausea, heartburn, pedal edema, tachycardia

Contraindicated in heart failure, possibly except for amlodipine

Use of short-acting nifedipine possibly associated with higher rate of myocardial infarction


2.5–20 mg once a day


2.5–10 mg twice a day


20–40 mg 3 times a day

Nicardipine, sustained-release

30–60 mg twice a day

Nifedipine, extended-release

30–90 mg once a day


10–60 mg once a day

Long-acting nifedipine, verapamil, or diltiazem is used to treat hypertension, but short-acting nifedipine and diltiazem are associated with a high rate of  myocardial infarction and are not recommended.

A calcium channel blocker is preferred to a beta-blocker in patients with angina pectoris and a bronchospastic disorder, with coronary spasms, or with Raynaud syndrome.

Direct renin inhibitor

Aliskiren, a direct renin inhibitor, is used in the management of hypertension. Dosage is 150 to 300 mg orally once a day, with a starting dose of 150 mg.

As with ACE inhibitors and angiotensin II receptor blockers, aliskiren causes elevation of serum potassium and creatinine. Aliskiren should not be combined with ACE inhibitors or angiotensin II receptor blockers in patients with diabetes or renal disease (estimated GFR < 60 mL/min).

Direct vasodilators

Direct vasodilators, including minoxidil and hydralazine (see table Direct Vasodilators for Hypertension), work directly on blood vessels, independently of the autonomic nervous system. Minoxidil is more potent than hydralazine but has more adverse effects, including sodium and water retention and hypertrichosis, which is poorly tolerated by women. Minoxidil should be reserved for severe, refractory hypertension.

Hydralazine is used during pregnancy (eg, for preeclampsia) and as an adjunct antihypertensive. Long-term, high-dose (> 300 mg/day) hydralazine has been associated with a drug-induced lupus syndrome, which resolves when the drug is stopped.

Direct Vasodilators for Hypertension


Usual Dose

Selected Adverse Effects*



10–50 mg 4 times a day

Positive antinuclear antibody test, drug-induced lupus (rare at recommended doses)

Augments vasodilating effects of other vasodilating drugs


1.25–40 mg twice a day

Sodium and water retention, hypertrichosis; possibly new or worsening pleural and pericardial effusions

Reserved for severe, refractory hypertension

* Both drugs may cause headache, tachycardia, and fluid retention and may precipitate angina in patients with coronary artery disease.


Main classes of diuretics used for hypertension (see table Oral Diuretics for Hypertension) are

  • Loop diuretics
  • Potassium-sparing diuretics
  • Thiazide-type diuretics

Diuretics modestly reduce plasma volume and reduce vascular resistance, possibly via shifts in sodium from intracellular to extracellular loci.

Loop diuretics are used to treat hypertension only in patients who have lost > 50% of kidney function; these diuretics are given at least twice a day (except for torsemide which can be given once a day).

Although the potassium-sparing diuretics do not cause hypokalemia, hyperuricemia, or hyperglycemia, they are not as effective as thiazide-type diuretics in controlling hypertension and thus are not used for initial treatment. Potassium-sparing diuretics or potassium supplements are not needed when an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker is used because these drugs increase serum potassium.

Thiazide-type diuretics are most commonly used. In addition to other antihypertensive effects, they cause a small amount of vasodilation as long as intravascular volume is normal. All thiazides are equally effective in equivalent doses; however, thiazide-type diuretics have longer half-lives and are relatively more effective at similar doses. Thiazide-type diuretics can increase serum cholesterol slightly (mostly low-density lipoprotein) and also increase triglyceride levels, although these effects may not persist > 1 year. Furthermore, levels seem to increase in only a few patients. The increase is apparent within 4 weeks of treatment and can be ameliorated by a low-fat diet. The possibility of a slight increase in lipid levels does not contraindicate diuretic use in patients with dyslipidemia.

All diuretics except the potassium-sparing distal tubular diuretics cause significant potassium loss, so serum potassium is measured monthly until the level stabilizes. Unless serum potassium is normalized, potassium channels in the arterial walls close and the resulting vasoconstriction makes achieving the blood pressure (BP) goal difficult. Patients with potassium levels < 3.5 mEq/L (< 3.5 mmol/L) are given potassium supplements. Supplements may be continued long-term at a lower dose, or a potassium-sparing diuretic (eg, daily spironolactone 25 to 100 mg, triamterene 50 to 150 mg, amiloride 5 to 10 mg) may be added. Potassium supplements or addition of a potassium-sparing diuretic is also recommended for any patients who are also taking digitalis, have a known heart disorder, have an abnormal ECG, have ectopy or arrhythmias, or develop ectopy or arrhythmias while taking a diuretic.

In most patients with diabetes, thiazide-type diuretics do not affect control of diabetes. Uncommonly, diuretics precipitate or worsen type 2 diabetes in patients with metabolic syndrome.

A hereditary predisposition probably explains the few cases of gout due to diuretic-induced hyperuricemia. Diuretic-induced hyperuricemia without gout does not require treatment or discontinuation of the diuretic.

Diuretics may slightly increase mortality in patients with a history of heart failure who do not have pulmonary congestion, particularly in those who are also taking an ACE inhibitor or angiotensin II receptor blocker and who do not drink at least 1400 mL (48 oz) of fluid daily. The increased mortality is probably related to diuretic-induced hyponatremia and hypotension.

Oral Diuretics for Hypertension


Usual Dose*

Selected Adverse Effects

Loop Diuretics


0.5–2 mg twice a day

Hyperkalemia, hyponatremia, hypomagnesemia, dehydration, postural hypotension, tinnitus, hearing loss

Ethacrynic acid

25–100 mg once a day


20–320 mg twice a day


5–100 mg once a day

Potassium-sparing diuretics


5–20 mg once a day

Hyperkalemia (particularly in patients with renal failure and in patients treated with an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, or nonsteroidal anti-inflammatory drug), nausea, gastrointestinal distress, gynecomastia, menstrual irregularities (with spironolactone); possibly increased blood levels of lithium


25–100 mg once a day


25–100 mg once a day


25–100 mg once a day

Thiazides and thiazide-type diuretics (chlorthalidone and indapamide)


2.5–5 mg once a day (maximum: 20 mg)

Hypokalemia (which increases digitalis toxicity), hyperuricemia, glucose intolerance, hypercholesterolemia, hypertriglyceridemia, hypercalcemia, sexual dysfunction in men, weakness, rash; possibly increased blood levels of lithium


62.5–500 mg twice a day (maximum: 1000 mg)


12.5–50 mg once a day


12.5–50 mg once a day


12.5–50 mg once a day


1.25–5 mg once a day


2.5–5 mg once a day

* Larger doses may be required in patients with renal failure.

† Aldosterone receptor blockers.

More Information

The following is an English-language resource that may be useful. Please note that THE MANUAL is not responsible for the content of this resource.

  • 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.

Drugs Mentioned In This Article

Drug Name Select Trade
Perindopril erbumine Perindopril erbumine
Hydrochlorothiazide MICROZIDE
Bendroflumethiazide Bendroflumethiazide
Methyclothiazide No US brand name
Ethacrynic acid EDECRIN
Spironolactone ALDACTONE
chlorthalidone THALITONE
Chlorothiazide DIURIL
Trandolapril MAVIK
triamterene DYRENIUM
Candesartan ATACAND
Telmisartan MICARDIS
Propranolol INDERAL
Nicardipine CARDENE
Nisoldipine SULAR
Amlodipine NORVASC
carvedilol COREG
Furosemide LASIX
Benazepril LOTENSIN
Irbesartan AVAPRO
Eprosartan TEVETEN
Guanfacine TENEX
Felodipine PLENDIL
Olmesartan BENICAR
acebutolol SECTRAL
Azilsartan EDARBI
methyldopa No brand name
bisoprolol ZEBETA
eplerenone INSPRA
verapamil CALAN
Captopril CAPOTEN
amiloride MIDAMOR
Quinapril ACCUPRIL
betaxolol BETOPTIC
Enalapril VASOTEC
torsemide DEMADEX
Valsartan DIOVAN
Terazosin HYTRIN
Aliskiren TEKTURNA
carteolol OCUPRESS
Nebivolol BYSTOLIC
Doxazosin CARDURA
minoxidil ROGAINE
Clonidine CATAPRES
Ramipril ALTACE
Losartan COZAAR
atenolol TENORMIN
lithium LITHOBID

Copyright © 2022 Merck & Co., Inc., known as MSD outside of the US, Kenilworth, New Jersey, USA. All rights reserved. Merck Manual Disclaimer